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Abdominal obesity has been associated with liver fat storage. However, the relationships between other body composition depots
and metabolic syndrome features with hepatic fat are still unclear. We examined abdominal and thigh adipose tissue (AT)
compartments associations with liver fat in 140 overweight and obese premenopausal Caucasian women. Blood lipids and,
proinﬂammatory and atherothrombotic markers associations with hepatic fat were also analyzed. A larger visceral AT (VAT) was
related with liver fat (P<0.05). Contrarily, thigh subfascial AT was inversely related to liver fat (P<0.05). Increased fasting
insulin, triglycerides, PAI-1 concentrations, and a higher total-cholesterol/HDL-cholesterol ratio were also associated with hepatic
fat, even after adjustment for VAT (P<0.05). Thigh subfascial adiposity was inversely associated with liver fat, suggesting a
potential preventive role against ectopic fat storage in overweight and obese women. These results reinforce the contribution of an
abdominal obesity phenotype associated with a diabetogenic and atherothrombotic proﬁle to liver lipotoxicity.
1.Introduction
Obesity-related comorbidities seem to be more closely
related to body fat distribution (e.g., upper versus lower,
visceral versus subcutaneous, and truncal versus peripheral)
rather than the total amount per se [1]. Abdominal obesity
is a relevant predictor of a higher metabolic risk, assuming
that insulin resistance (IR) is the common link between
visceral adiposity and dyslipidemia [2–4], type 2 diabetes
mellitus (DM) [5, 6], liver fat storage [7], hypertension
[8], and other cardiovascular diseases (CVD) [8–10]. Two
major pathophysiological hypotheses have been proposed
to explain the dysmetabolic milieu observed in abdominal
obese individuals. It has been proposed that neuroendocrine
perturbations, mediated by hypothalamic-pituitary-adrenal
(HPA)axisstimulation,areresponsibleforIRandabdominal
obesity [11, 12]. Alterations in cortisol secretion, inhibition
ofsteroidandgrowthhormonesproduction,andstimulation
of sympathetic nervous centers are some of the dysfunctions
which may precipitate metabolic disturbances [12]. Con-
versely, according to the “portal hypothesis,” the increased
lipolytic activityin visceraladipocytes leadsto anaugmented
release of free fatty acids (FFA) into portal circulation,
promoting liver fat storage that is accompanied by hepatic
metabolism disturbances and IR [6, 13, 14].
In this context, abdominal obesity has been associated
with ectopic fat storage, deﬁned as fat accumulation outside
“classical” depots such as heart, skeletal muscle, pancreas,
and liver [15]. Liver fat is associated with obesity, increased
concentrations of plasma FFA, as well as with the IR
degree, both in obese and type 2 DM patients [14, 16, 17].
Furthermore, a lower liver-to-spleen ratio (LSR), a reliable
index of liver fat [18], has been independently associated
with visceral adiposity [7, 19, 20], hepatic IR [6, 17, 19, 21],
dyslipidemia, and several other metabolic syndrome features
[6, 7, 19, 22]. Additionally, hepatic steatosis has also been2 Journal of Lipids
associated with IR and major CVD risk factors due to a
combination of abnormalities including increased liver FFA
inﬂuxandsynthesis, decreasedFFAoxidation, increasedvery
low-density lipoprotein (VLDL) particles secretion, and a
low-grade chronic proinﬂammatory state [21, 23].
Although evidence has highlighted the independent
contributions of both visceral adiposity and liver fat to an
increased metabolic risk in obese and type 2 DM patients, it
is not totally clear if liver fat is additionally associated with
other speciﬁc inﬂammatory and atherothrombotic markers
[6, 7, 19, 22]. On the other hand, despite the recognized
abdominal obesity relevance to ectopic fat storage, little is
known about the relationships of other fat compartments,
such as thigh AT, with liver fat, and consequently with
hepatic steatosis. In fact, only one study developed in type
2 DM patients has reported that thigh subfascial AT was
associated with both liver fat and IR [6] features. Therefore,
based on previously deﬁned criteria [18], the current study
examined the independent associations of abdominal and
thigh AT compartments with hepatic fat in overweight and
obese premenopausal Caucasian women. Additionally, this
studyinvestigatedtheassociationsofliverfatwithmetabolic,
proinﬂammatory, and atherothrombotic risk factors.
2.MaterialsandMethods
2.1. Subjects. Participants in this investigation were 140
premenopausal overweight and obese Caucasian women,
recruited from the Lisbon (Portugal) area by public
advertisements. Participants were part of a 2-year weight
management program, as described elsewhere [24]. Study
inclusion criteria were the following: subjects could not
be pregnant or trying to become pregnant, >24 years,
>24.9kg/m2 body mass index (BMI), were not under any
medication that could aﬀect weight, body composition or
liver metabolism, had no clinical or laboratory evidence of
liver or spleen disease, and had no history of cancer in the
last ﬁve years. Exclusion criteria were ongoing hormonal
medication, history of CVD, stroke, hypertension, type 2
DM, Cushing syndrome, hormonal dysfunction, resting and
exerciseabnormalelectrocardiograms,aswellasthepresence
of drinking habits. Subjects that were undertaking oral
medication to treat hypertriglyceridemia, hyperglycemia, or
hypercholesterolemia were also excluded. All subjects were
informed about the purpose, nature and study design before
giving their full written consent to participate. The study
protocol was performed according to the principles of the
Helsinki Declaration and was approved by The Human
Subjects Institutional Review Board of the Faculty of Human
Movement, Technical University of Lisbon.
2.2. Body Composition Assessments
2.2.1. Anthropometric Variables. Height was measured to
the nearest 0.1cm with a stadiometer (Seca, Hamburg,
Germany). Body weight was measured to the nearest 0.01kg
onapreviouscalibratedscaleafterremovingshoesandheavy
clothing. Abdominal sagittal diameter (SD), waist circumfer-
ence (WC), and hip circumference (HC) measurements were
performed according to Lohman et al. [25] procedures. Both
W Ca n dH Cm e a s u r e m e n t sw e r et a k e nw i t has t i ﬀ ﬁbreglass
tape to the closest 0.1cm. All anthropometric variables were
measured by trained technicians and repeated 3 times, with
the mean value being used. BMI was calculated as weight
divided by height squared (kilograms per square meter), and
waist-to-hip ratio (WHR) was deﬁned as the WC divided by
HC.
2.2.2. Dual Energy X-ray Absorptiometry (DXA). Trunk
fat mass (TFM), total body fat mass (TBFM), and total
body lean mass (TBLM) were measured by a pencil beam
mode DXA (QDR-1500 Hologic, Waltham, Mass, USA).
All measurements were made with volunteers in the supine
position with their arms separated from their trunk. The
same technician performed the all the scans and completed
the analysis according to the operator’s manual. The intraob-
server coeﬃcient of variation (CV) for TBFM and TBLM
was 2.0% and 1.7%, respectively. A 0.5% technical error for
%TBFM was obtained as estimated in 2 repeated measures
performed on 10 subjects.
2.2.3.MeasurementofAbdominalAdiposeTissue Distribution.
With the subjects supine and arms extended above their
head, a single cross-sectional CT (Somaton Plus; Siemens,
Sorheim, Germany) L4-L5 intervertebral space image was
acquired to measure abdominal AT compartments, as
described elsewhere [1]. All images were obtained using
120kVp, 480mA, and 512 × 512 matrix with a 48-cm ﬁeld
of view. Total abdominal adipose tissue (TAAT), abdominal
subcutaneous adipose tissue (Ab SAT), superﬁcial and deep
Ab SAT, and visceral AT (VAT) areas were measured. The
boundary between VAT and Ab SAT was deﬁned using the
abdominal and oblique muscles in continuity with the deep
fascia of the paraspinal muscles and the anterior aspect
of the vertebral body [26]. The subcutaneous fascia was
used to diﬀerentiate Ab SAT into its superﬁcial and deep
compartment [1].
2.2.4. Measurement of Thigh Adipose Tissue and Muscle
Distribution. Using the same scanparameters, contiguous 7-
mm-thick cross-sectional images of both legs were obtained
between the inferior ischial tuberosity and the superior
border of the patella. Total thigh adipose tissue (TTAT),
total thigh subcutaneous AT (TTSAT), thigh subfascial AT
(TTSFAT), and muscle tissue areas and attenuations were
measured.Thetissuesvolumes(cubiccentimetres)identiﬁed
in each image were calculated by multiplying the image
thickness (7mm) by the tissue area (square centimetres).
Thigh AT volume (litters) was then converted to mass units
(kilograms)multiplyingthevolumebytheassumedconstant
of fat density (0.92kg/L) [27]. Total thigh muscle mass
was also calculated multiplying its volume by the constant
density assumed for AT-free skeletal muscle (1.04kg/L)
[27]. From the thigh scans performed, it was selected a
single slice located at the mid-point distance between both
anthropometric markers previously described to image mid-
thigh AT and muscle tissue distribution.
2.2.5. Measurement of Liver Fat. A 7-mm-thick crosssec-
tional image at T11-T12 intervertebral space was acquiredJournal of Lipids 3
to measure both liver and spleen CT attenuations, which
were determined by calculating the mean Hounsﬁeld units
(HUs) of three regions of interest (ROI) (liver ROI had
∼120mm2, located 2 in right lobe and 1 in left lobe;
spleen ROI had ∼75mm2). As previously described [6], all
ROI were consistently selected in peripheral parenchyma
areas, away from artefacts, major blood vessels and other
areas of inhomogeneity. The ratio of mean liver to spleen
attenuation values, deﬁned as liver-to-spleen ratio (LSR),has
been deﬁned as reliable index of liver fat [18]. Fatty liver was
present when LSR < 1[ 6].
2.2.6. Measurements Repeatability. The repeatability for
abdominal and thigh adipose and muscle tissue compart-
ments was calculated in 30 women chosen randomly from all
subjects. One technician performed the repeated analyses on
the same images, separated by 3 months. The intraobserver
coeﬃcient of variation (CV) for VAT and TAAT was,
respectively,0.9%and0.7%.ForAbSAT,deepandsuperﬁcial
Ab SAT, the intra-observer CV was, respectively, 0.8%, 2.8%,
and 3.1%. For mid-thigh muscle tissue, total mid-thigh AT
and subfascial AT (SFAT), the intra-observer CV was 0.1%,
0.4%, and 2.5%, respectively. Repeatability for liver and
spleen measurements was also examined; the CV found for
LSR was 2.2%.
2.2.7. Image Analysis. Based on image morphology, CT
data were analysed by speciﬁc software (Slice-O-matic,
Version 4.2, Tomovision, Montreal, Canada). A combination
of watershed techniques and edge detection ﬁlters was
employed. Standard HU ranges for adipose tissue (−190 to
−30HU) and skeletal muscle (0 to +100HU) were used to
compute the tissue segmentation [28]. It was also measured,
inbothlegs,thehigh-density(30to100HU)andlow-density
muscle areas (0 to 30HU) [28]. Thigh fascia was used as
boundary to demarcate the subcutaneous from subfascial AT
[28].
2.3. Blood Analysis. After a 12-hour overnight fast, venous
blood samples were collected at antecubital vein. Samples
were centrifuged at 4◦C, and plasma was stored at −70◦C
until analysis. Measurement of triglycerides (TG), uric acid,
total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C), and high-density lipoprotein cholesterol (HDL-
C) was made by enzymatic colorimetric methods. Fast-
ing insulin was determined by electrochemiluminescence
immunoassay (ECLIA), glycemia was assessed by hexokinase
method and interleukin-6 (IL-6) was measured by chemi-
luminescence immunoassay. Tumor necrosis factor-alpha
(TNF-α) was measured using a high-sensitivity enzyme-
linked immunosorbent assay (ELISA) principle. Plasmino-
gen activator inhibitor-1 (PAI-1) was measured in iced
citrated plasma using the Coatest PAI method (enzyme
immunoassay—EIA), and ﬁbrinogen concentrations were
measured by clotting time. Hemoglobin A1c (Hb A1c)
was determined by high-pressure liquid chromatography
(HPLC). Serum adiponectin and leptin concentrations as
well as urine cortisol were measured by radioimmunoassay
(RIA).
Microalbuminuria, C-reactive protein (CRP), apolipo-
protein A1 (apo A1), and apolipoprotein B100 (apo B100)
plasma concentrations were measured by high-sensitivity
particle-enhanced turbidimetric assay. Alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) were
determined by a kinetic method. Samples were measured in
duplicate, and the average of the two values was used in the
statistical analyses. All blood samples were taken during the
follicular stage of menses.
2.4. Blood Pressure. At the same day of body composition
measurements, systolic and diastolic blood pressures (BP)
were measured in seated position with a semiautomatic
oscillometric recorder (Dinamap, Critikon, Tampa, FL) after
a 5-minute rest period. A suitable cuﬀ size was applied to
participant’s upper arm at the heart level, and the mean of
threemeasurementsineacharm,separatedby1-minutetime
lapse, was calculated. Previously to the baseline measure-
ments, all subjects were clinically evaluated by the program
physicianwhowasresponsiblefortheﬁnal(clinical)decision
related with the inclusion or exclusion of each subject in the
study sample. Regarding hypertension criteria, all subjects
included in our study were not hypertensive. However, at the
same day of body composition measurements, one subject
revealed a mean systolic blood pressure of 175mmHg (DBP:
93mmHg) while in another subject was measured a mean
diastolic blood pressure of 105mmHg (SBP: 150mmHg).
In order to conﬁrm the nonhypertensive status previously
assigned, both subjects repeated the assessments in another
day of the same week, and the non-hypertensive status
was conﬁrmed. For the study purposes, since all laboratory
measurements were speciﬁcally made at the same day, we
included both subjects in the study and in data analysis.
2.5. Premenopausal and Physical Activity Status. The study
physician, based on her menstrual history, determined the
premenopausal status of each study volunteer; the pre-
menopausal stage was considered if women reported regular
menstrual cycles. Daily physical activity status was assessed
by proportional actigraphy which measure the time spent
in diﬀerent daily activities based on the number of counts
per minute (Computer Science and Applications, Model
AM7164, FL, USA).
2.6. Drinking Habits. The amount of alcohol intake was
determinedusingaquestionnairecontaininginformationon
the daily alcohol intake of various alcoholic beverages. One
alcoholic unit corresponded to a glass of wine, a can of beer,
or a measure of spirits, and contains 12-13g of ethanol.
2.7. Statistical Analyses. Unless otherwise is indicated, data
are presented as means ± SD. Control for normality and
homoscedasticity of study variables was conducted. When
necessary, log transformations were used to normalize dis-
tributions. Multiple linear regressions, adjusted for age and
BMI, were performed to study the independent associations
of liver-to-spleen ratio with major metabolic syndrome fea-
tures,andinﬂammatoryandatherothromboticdisturbances.
Adjusting for the same variables, independent relations of
LSR with anthropometric markers, abdominal and thigh4 Journal of Lipids
adipose and muscle tissue compartments were also studied.
Additional multiple linear regressions, adjusted for age, fat
mass, and VAT, were performed to study the associations
betweenLSRandallthemetabolicsyndromeproﬁlemarkers.
In order to facilitate the comparisons of the results
obtained in the multiple linear regression models, standard-
ized beta coeﬃcients were presented. To determine how
much the independent variables were linearly related to
one another, the multicolinearity was studied by statistic
tolerance (1-R2), being the stability of the regression model
disturbed by multicolinearity if tolerance was inferior to 0.1.
Statistical signiﬁcance was set at P < 0.05. Statistical analyses
were performed using the SPSS version 13.0 for Windows
(SPSS, Chicago, Ill, USA).
3. Results
Most subjects were obese. Both body weight and BMI
revealed a wide range of variation (mean ± sd: 78.1 ± 1.0kg,
range: 59.1–107.8kg; 30.4 ± 0.3kg/m2, 25.1–45.2kg/m2,
resp.). The sample age varied between 25 and 49 years
(38.3 ± 0.5yrs). At baseline, very few subjects included
small amounts of physical activity in their daily routine.
In fact, the majority of the study subjects included were
sedentary,since94.4%ofthedailytimewasspentinactivities
with intensities under 100 counts per minute (data not
shown). Subject’s anthropometric and body composition
characteristics are presented in Table 1. Similarly to BMI,
both abdominal and thigh AT compartments revealed a wide
variation. An increased WC was observed in 43.9% of the
subjects [29]. VAT was the minor constituent of abdominal
AT area (23.6%). Superﬁcial and deep Ab SAT areas were
similar, comprising each one, approximately, half of total
Ab SAT depot. While TTAT mass represented 57.9% of total
thigh mass, LDM was the smallest compartment (19.8%) of
mid-thigh muscle area.Thefattyliverprevalenceobserved in
our sample of overweight and obese premenopausal women
was 2.9%.
Metabolic syndrome features are presented in Table 2.
According to the Adult Treatment Panel (ATP) III criteria
[29], hypertriglyceridemia was found in 22.3% of the
subjects, and hypertension assumed a 21.4% prevalence rate.
In our sample, lower HDL-C concentrations were found in
44.5% of the subjects, and 9.3% of the women met the ATP
III criteria for metabolic syndrome. However, only 0.7% of
the study subjects revealed hyperglycemia.
Age was not associated with LSR (β = 0.118, P > 0.05).
On the contrary, both weight and BMI were inversely asso-
ciated with LSR, even when adjusting for age (β = −0.235,
P < 0.01; β = −0.225, P < 0.01, resp.). The results of
simultaneously entering each anthropometric and body
composition marker to predict LSR, adjusting for age
and BMI, are shown in Table 3. Higher SD values were
independently associated with a lower LSR representing an
increasedliverfatstorage.Similar associationswereobserved
when using liver attenuation as the dependent variable.
Despitenotsigniﬁcant,WHR,aswellastotalbodyandtrunk
fat mass revealed an inverse association trend with liver fat.
Table 1: Subjects anthropometric data, body composition data
(DXA), fat and muscle distribution data (CT), and liver and spleen
variables.
Mean ± SD Range
Anthropometric data
WC, cm 87.2 ± 0.8 71.1–123.4
Waist-to-hip ratio 0.78 ± 0.01 0.64–0.99
Sagittal diameter, cm 20.5 ± 0.2 16.3–31.0
Fat mass
TFM, kg 18.0 ± 0.4 9.4–32.3
TBFM, kg 36.1 ± 0.7 23.5–60.3
TBLM, kg 41.2 ± 4.62 29.7–55.6
Abdominal adipose tissue
TAAT, cm2 470.9 ± 12.1 211.9–910.8
VAT, cm2 111.3 ± 4.3 24.9–266.8
Ab SAT, cm2 353.6 ± 9.1 145.0–633.4
Superﬁcial, cm2 192.2 ± 5.0 90.6–384.2
Deep, cm2 161.8 ± 5.4 54.7–344.9
Thigh compartments
Thigh AT, cm2 270.7 ± 6.9 132.9–509.1
Thigh SAT, cm2 261.6 ± 6.8 129.4–501.6
Thigh SFAT, cm2 3.5 ± 0.2 1.0–11.9
Muscle, cm2 234.3 ± 2.6 176.3–324.7
Muscle Attenuation, HU 44.0 ± 0.3 33.4–51.7
HDM, cm2 189.3 ± 2.3 145.7–264.4
LDM, cm2 32.8 ± 0.9 15.7–80.0
TTAT, kg 8.4 ± 2.1 4.0–14.8
TTSAT, kg 7.9 ± 2.1 3.8–14.0
TTSFAT, kg 0.6 ± 0.2 0.3–1.5
TTMT, kg 6.1 ± 0.9 4.4–10.3
Liver and spleen variables
Liver attenuation, HU 59.8 ± 0.8 −5.6–71.0
Spleen attenuation, HU 46.4 ± 0.4 34.0–57.5
LSR 1.30 ± 0.02 −0.11–1.82
Values are means ± SD. WC, waist circumference; TFM, trunk fat mass;
TBFM, total body fat mass; TBLM, total body lean mass; TAAT, total
abdominal adipose tissue; VAT, visceral adipose tissue; Ab, abdominal;
SAT, subcutaneous adipose tissue; Thigh SAT, mid-thigh subcutaneous
adipose tissue; SFAT, subfascial mid-thigh adipose tissue; HU, Hounsﬁeld
units; HDM, mid-thigh high-density muscle; LDM, mid-thigh low-density
muscle; TTAT, total thigh adipose tissue; TTSAT, total thigh subcutaneous
adipose tissue; TTSFAT, total thigh subfascial adipose tissue; TTMT, total
thigh muscular tissue; HU, Hounsﬁeld units; LSR, liver-to-spleen ratio.
In further analysis, after adjusting for HC, a larger WC was
related with a lower LSR (β = −0.203, P < 0.05).
In Table 4 are presented the independent associations
of abdominal AT depots and thigh body composition
compartments with LSR, after adjustment for age and BMI.
Higher VAT areas were associated with a lower LSR. On the
contrary, a higher thigh SFAT area was related with a higher
LSR. These associations remained signiﬁcant when using
liver attenuation as a dependent variable and adjusting for
the same confounders. Furthermore, thigh SFAT remained
positively associated with LSR, independently of WC (β =
0.166, P < 0.05).Journal of Lipids 5
Table 2: Metabolic syndrome characteristics of the study popula-
tion (n = 140).
Mean ± SD Range
Glucose homeostasis
Fasting insulin, μIU/mL 8.2 ± 0.3 2.40–17.9
Fasting glycaemia, mg/dL 89.5 ± 0.7 73.0–113.0
Hb A1c, % 4.9 ± 0.4 4.0–7.0
Lipid proﬁle
TC, mg/dL 194.7 ± 3.9 101.0–307.0
HDL-C, mg/dL 54.1 ± 1.1 29.0–91.0
LDL-C, mg/dL 123.5 ± 3.6 45.0–255.0
TC/HDL-C ratio 3.7 ± 1.1 2.0–9.6
LDL-C/HDL-C ratio 2.4 ± 0.1 0.9–6.1
Apo A1/Apo B100 ratio 1.7 ± 0.1 0.8–3.3
Triglycerides, mg/dL 101.5 ± 4.9 32.0–329.0
Blood pressure
Systolic, mm Hg 120.7 ± 1.4 90.0–175.0
Diastolic, mm Hg 75.8 ± 0.9 50.0–101.0
Liver enzymes
ALT, IU/L 18.2 ± 0.5 9.0–43.0
AST, IU/L 16.2 ± 0.6 5.0–44.0
Inﬂammation
hs-CRP, mg/dL 0.45 ± 0.03 0.03–1.14
Cytokines
IL-6, pg/mL 10.3 ± 0.6 0.8–31.5
TNF-α,p g / m L 3 . 8± 0.2 0.9–14.1
Hypercoagulation
PAI-1, ng/mL 21.2 ± 2.0 1.0–100.0
Fibrinogen, mg/dL 369.4 ± 6.5 201.0–552.0
Adipokines
Leptin, ng/mL 32.9 ± 43.3 0.9–167.4
Adiponectin, ng/mL 9.2 ± 6.4 2.9–41.0
Urine
Uric acid, mg/dL 4.4 ± 1.0 2.40–8.50
Microalbuminuria, μg/min 2.7 ± 0.7 0.5–89.8
Cortisol, μg/day 41.0 ± 1.7 6.0–105.0
Values are means ± S D .H bA 1 c ,h e m o g l o b i nA ( 1 c ) ;T C ,t o t a lc h o l e s -
terol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; Apo A1, apolipoprotein A1; Apo B, apolipoprotein
B100; ALT, alanine aminotransferase; AST, aspartate aminotransferase; hs-
CRP, high-sensitive C-reactive protein; IL-6, interleukin-6; TNF-α,t u m o r
necrosis factor-alpha; PAI-1, plasminogen activator inhibitor-1.
Independent associations of metabolic syndrome fea-
tures, inﬂammatory and atherothrombotic risk factors with
liver fat, adjusting for age and BMI, are presented in Table 5.
Higher fasting insulin, TG, liver transaminases, PAI-1, and
uric acid concentrations, as well as higher TC/HDL-C and
LDL-C/HDL-C ratios were associated with a lower LSR.
When adjusted for VAT, these health risk factors remained
signiﬁcantly related with LSR (P < 0.05). The explained
variance for each metabolic risk factor studied to LSR varied
between 3.6% and 24.8%, showing higher values for liver
transaminases, TC/HDL-C ratio, and fasting insulin. When
adjusting for age and BMI and using liver attenuation as
Table 3: Independent contributions (standardized beta coeﬃ-
cients) of anthropometric and body composition variables to liver-
to-spleen ratio, adjusted for age and BMI.
Liver-to-spleen ratio Percentage of variance
explained∗∗ (%)
WC, cm −0.229 7.7#
HC, cm 0.125 7.0#
WHR −0.145 7.9#
SD, cm −0.383∗ 10.1#
TFM, kg −0.221 7.4#
TBFM, kg −0.111 6.5#
TBLM, kg −0.077 6.7#
All variables were entered in the regression models as continuous variables.
Age did not present any independent association with the anthropometric
studied variables.
∗∗ Variance explained by age, BMI, and the studied variable.
# Independent associations of BMI,P< 0.01.
∗P < 0.05.
†P < 0.01.
‡P < 0.001.
Table 4: Independent contributions (standardized beta coeﬃ-
cients) of abdominal adipose tissue depots and thigh body compo-
sition compartments to liver-to-spleen ratio, adjusted for age and
BMI.
Liver-to-spleen ratio Percentage of variance
explained∗∗ (%)
TAAT, cm2 −0.234 8.4
Ab SAT, cm2 −0.136 6.8
Superﬁcial, cm2 0.014 6.3
Deep, cm2 −0.133 7.3
VAT, cm2 −0.241∗ 9.2
Mid-thigh AT, cm2 0.148 7.1
Mid-thigh SAT, cm2 0.129 7.1
Mid-thigh SFAT, cm2 0.295† 12.5
Muscle, cm2 0.005 6.2
HDM, cm2 −0.036 6.4
LDM, cm2 0.145 7.3
All variables were entered in the regression models as continuous variables.
While BMI revealed independent associations with all body composition
variables (P < 0.01), age did not present any independent relation with the
studied variables.
∗∗ Variance explained by age, BMI, and the studied variable.
∗P < 0.05.
†P < 0.01.
dependent variable, similar associations to those described
earlier were found, except for fasting insulin and uric acid
(P > 0.05).
4. Discussion
Our primary ﬁndings were that, in a sample of overweight
and obese premenopausal women, a higher thigh SFAT area
was associated with a higher LSR, representing a lower liver
fat storage, independently of age and BMI. Additionally,
we found that for a given WC, increased thigh SFAT areas6 Journal of Lipids
Table 5: Independent contributions (standardized beta coeﬃcients) of metabolic syndrome components to liver-to-spleen ratio, adjusted
for age and BMI.
Liver-to-spleen
ratio
Percentage of variance
explained∗∗ (%)
Glucose homeostasis
Fasting insulin, μIU/mL −0.218∗ 10.1
Fasting glycemia, mg/dL −0.069 6.6
Hb A1c, % 0.001 6.2
Lipid proﬁle
TC, mg/dL −0.067 6.5
HDL-C, mg/dL 0.107 7.2
LDL-C, mg/dL −0.021 6.2
TC/HDL-C ratio −0.284‡ 13.1
LDL-C/HDL-C ratio −0.181∗ 9.0
Apo A1/Apo B100 ratio 0.067 6.5
Triglycerides, mg/dL −0.257† 11.9
Blood pressure
Systolic, mmHg 0.047 6.6
Diastolic, mmHg 0.177∗ 9.4
Liver enzymes
ALT, IU/L −0.437‡ 24.8
AST, IU/L −0.346‡ 17.8
Inﬂammation
hs-CRP, mg/dL −0.006 3.6
Cytokines
IL-6, pg/mL −0.054 6.1
TNF-α, pg/mL 0.013 6.1
Hypercoagulation
PAI-1, ng/mL −0.208∗ 9.7
Fibrinogen, mg/dL −0.011 6.3
Adipokines
Leptin, ng/mL −0.085 6.8
Adiponectin, ng/mL 0.041 6.4
Urine
Uric acid, mg/dL −0.178∗ 8.9
Microalbuminuria, μg/min 0.071 6.7
Cortisol, μg/day −0.096 7.1
All variables were entered in the regression models as continuous variables. While age did not present any independent relation to the studied variables, BMI
revealed an independent association with all metabolic syndrome features (P < 0.01).
∗∗ Variance explained by age, BMI and the studied variable.
∗P < 0.05.
†P < 0.01.
‡P < 0.001.
were also signiﬁcantly related with higher LSR values. To
our knowledge, these associations between thigh SFAT and
both LSR and liver attenuation are novel observations that
may suggest an indirect preventive role of this thigh AT
depot against ectopic liver fat storage, and therefore, against
hepatic steatosis, in overweight or obese premenopausal
women without type 2 DM. It has been suggested that
femoral-gluteal AT compartments may function as a “sink”
for circulating FFA [30]. When compared with visceral
adipocytes, these thigh adipocytes are less sensitive to
stimulated lipolysis and reveal a relatively higher lipoprotein
lipase activity, important in FFA uptake from the circulation
[31]. These metabolic characteristics may prevent liver li-
potoxicity and counteract the inevitable physiologic cascade
observed inabdominal obesesubjects,responsible forIRand
other secondary metabolic disturbances, such as a multiple
proinﬂammatory cytokine response. In this context, several
studies have been reporting that peripheral fat mass (PFM),
measured by DXA (unable to diﬀerentiate the diﬀerent
thigh adipose tissue compartments), is an independentJournal of Lipids 7
predictor of a lower cardiovascular risk [32, 33]. This
potential protective role of PFM in metabolic disturbances
and atherogenicity may be, in part, explained by adiponectin
insulin sensitizing eﬀects [34]. In fact, it has been suggested
that speciﬁcally the thigh subcutaneous AT, a major con-
tributor for the circulating adiponectin, could mediate these
counteractingeﬀects[35].Althoughlittleisknownregarding
the necessity of making a clear distinction between the
metabolic activity and role of the femoral subcutaneous and
subfascial fat depots, it was already assumed that subfascial
thigh fat, representing the intermuscular (within muscle
ﬁbbers) fat deposition [6], is characterized by a diﬀerent
lipolysis rate and cytokine secretory proﬁle, compared to
subcutaneous femoral fat [1, 35].
In our study developed in overweight and obese pre-
menopausal women, beside the associations found sug-
gesting that thigh subfascial AT may confer a metabolic
protection against detrimental ectopic fat storage in the
liver, although not signiﬁcant, a similar trend was observed
between both total thigh AT mass and subcutaneous AT and
LSR. In this context, the metabolic diﬀerences previously
described between both thigh adipose tissue compartments
might underlie diﬀerent mechanisms that could interfere
with the relations found in this study.
Other studies conducted with type 2 DM patients have
also reported that thigh SFAT is associated with hepatic
fat [6]a n dI R[ 6, 28]. Indeed, in a recent study developed
with 83 type 2 DM patients, it was observed that fatty liver
was inversely related with femoral subfascial AT and with
visceral adiposity [6], independently of the eﬀects of VAT
and BMI. More than interpreting these results as an evidence
suggesting a causative role of thigh SFAT to fatty liver
pathogenesis, the authors have proposed that SFAT together
with fatty liver are special adiposity depots related with IR
pathogenicity in type 2 DM. These results obtained in type
2 DM patients contrast with our observations in overweight
andobesepremenopausalCaucasianwomen,suggestingthat
this body composition area warrants more research in order
to clarify the possible underlying mechanisms. However, one
possible explanation for the diﬀerences found between both
studies might be related with the fact that the unfavourable
metabolic proﬁle normally present in type 2 DM patients
contrasts with a relative healthy metabolic pattern found
in our sample of overweight and obese premenopausal
women (only 9.3% of the women met the ATP III criteria
for metabolic syndrome).
The role of abdominal obesity on ectopic liver fat storage
and the concomitant metabolic abnormalities was already
addressed [6, 7, 36, 37]. In a study with 144 patients with
hepatic steatosis, clinically characterized by hepatocyte fat
inﬁltration and often described as fatty liver, BMI was the
unique independent predictor of the steatosis degree [38].
Another two studies have also reported that, both in obese
patients [39] and in living liver donors [40], BMI was
associated with the steatosis severity. In our study with
overweight and obese premenopausal Caucasian women, we
found that, independently of age, a higher weight, BMI
and sagittal diameter (but not WC) were associated with a
lower LSR. Despite the nonsigniﬁcant association veriﬁed
between LSR and WC when adjusting for age and BMI, in
fact, WC has been described as a better predictor of VAT
rather than SD. One explanation for this observation may be
related with the measurement procedures, which may vary
according to the method used; when WC is measured by
Lohman et al. [25] procedures, it is selected the narrowest
circumference in abdominal area—procedure adopted in
out study. Contrarily, according to the National Health and
Nutrition Examination Survey-NHANES III guidelines, WC
is measured immediately above the iliac crests increasing
the absolute mean values registered. In our study, despite
the nonassociation veriﬁed between LSR and WC when
adjusting for age and BMI, there is a trend that could
be signiﬁcant if adopted another measurement procedure.
The observation made in our study that, for a given WC,
increased thigh SFAT areas were also signiﬁcantly related
with a higher LSR seems to reinforce the importance of
taking into account the WC in this analysis. In addition,
another reason to justify the inclusion of WC in these
statistical analysis procedures is related with the fact that WC
seems to be clinically easer to measure rather than SD and
VAT(usuallyimplyingspeciﬁcequipmentandmorecomplex
procedures).
On the other hand, in a study with 221 chronic hepatitis
C patients [41], VAT, rather than BMI, was a signiﬁcant
predictor of hepatic steatosis. In fact, abdominal obesity
markers, such as WC [17, 20], WHR [20, 42], VAT [4, 7],
VAT/TAAT ratio [4, 7], and Ab SAT [20]h a v eb e e nm a r k e d l y
associated with liver fat. In our study, after adjustment for
HC, a larger WC was related with liver fat storage. Additional
adjustments for age, BMI, and thigh SFAT revealed that a
higher VAT area was independently associated with a lower
LSR (β = −0.250, P < 0.05), emphasizing the abdominal
obesity phenotype relevance to liver lipotoxicity [15]e v e ni n
a sample of overweight and obese premenopausal women.
This obesity phenotype relevance, additionally corroborated
in our sample by the fact that when adjusting for age,
BMI, and VAT the thigh SFAT did not remain signiﬁcantly
related with LSR (β = 0.053, P > 0.05), was, in fact, already
suggested in a previous study with type 2 DM patients [6]
andinotherrecentstudyreportingthatsurgicalVATremoval
could reverse hepatic IR [43]. The link between abdominal
adiposity and liver fat storage may be explained by the fact
that FFA are more easily mobilized from visceral AT rather
than Ab SAT depots, draining directly into the liver via
portal circulation [44]. The increased FFA liver inﬂux may
induce hepatic steatosis that might be responsible for other
metabolic disturbances, such as increased liver FFA and TG-
rich lipoproteins synthesis, adipocyte proliferation failure,
and insuﬃcient hepatocyte FFA oxidation [15, 19, 45]. In
addition, liver lipotoxicity may be accompanied by a low
chronic inﬂammatory state, which can promote a future
progression to nonalcoholic steatohepatitis (NASH) [45].
Despite evidence has been demonstrating the VAT-derived
FFA contribution to these pathophysiologic cascade, a recent
overview have also highlighted the role of FFA released
from abdominal subcutaneous adipocytes into systemic
circulationtothesehepaticdisturbances[46].Inthiscontext,
the results of our study with premenopausal overweight and8 Journal of Lipids
obese women are consistent with some emerging observa-
tions [7], suggesting that liver fat is strongly associated with
abdominal obesity and can also independently reﬂect an
unfavourable metabolic syndrome proﬁle.
Indeed, we observed that higher insulin, TG, liver
transaminases, PAI-1, and uric acid concentrations were
independently associated with a lower LSR. Furthermore,
higher TC/HDL-C and LDL-C/HDL-C ratios were also
related with lower LSR values. These metabolic markers
remained signiﬁcantly associated with liver fat, indepen-
dently of VAT (data not shown). Despite some evidence
have been proposing that hepatic fat storage is normally
preceded by VAT accumulation, our results are consistent
with other observations reporting that liver fat remains
associated with metabolic syndrome features independently
of total and visceral adiposity [22, 47]. In this sense, these
results suggest that hyperinsulinemia, hypertriglyceridemia
and hypercholesterolemia are relevant to the metabolic
cascade that mediates liver disturbances in overweight and
obese premenopausal women. Other studies developed with
bothinsulin-sensitive andinsulin-resistantsubjectshavealso
reported that liver fat was associated with IR markers [7]
and TG concentrations [5, 7]. Another study developed
with type 2 DM patients reported that the presence of
fatty liver was associated with a higher degree of IR and
dyslipidemia [6]. Hepatic steatosis has also been associated
with dyslipidemia, hyperinsulinemia, and IR not only in
obese subjects but also in lean subjects without glucose
intolerance [21]. Although the role of diabetes in hepatic
steatosis and in its progression to NASH still remains
unclear [45], the NHANES-III reported that simple IR
features, such as fasting insulin, Hb A1c, and C-peptide
concentrations, as well as abdominal obesity markers were
independently associated with ALT concentrations, the most
sensitiveindicatoroflivercellintegrity.Infact,increasedliver
transaminases concentrations are associated with obesity
severity and can also predict the liver injury degree [39, 48].
On the other hand, it is noteworthy that hyperinsulinemia
seems to play a key role in FFA metabolism and may
inhibit hepatocyte mitochondrial beta-oxidation, which can
additionally contribute to liver lipotoxicity. The inverse
associations of both PAI-1 and uric acid with LSR observed
in our study emphasize the ectopic liver fat storage relevance
to inﬂammatory and atherothrombotic metabolic syndrome
disturbances in overweight and obese premenopausal Cau-
casian women.
Despite several studies have been demonstrating that
metabolic disturbances are associated with ectopic liver fat
storage, including ours, Despr´ es et al. [49]h a v es u g g e s t e d
that it might be the lack of or a dysfunctional subcutaneous
adipose tissue that may be responsible for the increase in
ectopic fat deposition in the liver, heart, skeletal muscle and
pancreas which further increase the cardiovascular disease
and type 2 DM risk, rather than the inverse way. In order
to address this hypothesis, we investigate in our sample of
overweight and obese women the independent contribution
of LSR to each one of the metabolic syndrome markers
studied. Similarly to results previously reported, LSR was
associated with fasting insulin (β = −0.173, P < 0.001),
triglycerides (β = −0.205, P < 0.05), TC/HDL-C (β =
−0.212, P < 0.01), and LDL-C/HDL-C (β = −0.469, P <
0.05) ratios, and with both ALT (β = −0.354, P < 0.05)
and AST concentrations after adjustment for age, total fat
mass, and VAT. The explained variance of LSR to each
metabolic risk factor studied varied between 15.5% and
29.2%, showing higher values for TC/HDL-C and LDL-
C/HDL-C ratios, liver transaminases, and fasting insulin,
respectively. Despite the independent associations veriﬁed
between LSR and both PAI-1 (β = −0.232, P < 0.01) and uric
acid (β = −0.200, P < 0.05) concentrations when controlled
for age and BMI, they did not remain signiﬁcant in this new
treatment. The similarity of the independent associations
veriﬁed between LSR, and each one of the metabolic
syndrome markers studied in our sample suggests that a
biological continuum may underlie the relations making
hard to discriminate a cause-consequence interpretation.
Theroleofsomeadipocytokines,suchasleptinandTNF-
α in hepatic steatosis has also been increasingly studied.
Recent studies have reported that leptin can mediate lean
body tissues protection against lipotoxic damage [50], being
also relevant in lipogenesis blocking, and in muscle insulin-
sensitization and fatty acid oxidation enhancement [50].
However, hyperleptinemia, commonly present in visceral
obese patients, may aggravate IR and promote liver fat
storage. On the other hand, inﬂammatory cytokines, such
as TNF-α and IL-6, often overexpressed in obese patients
or overweight subjects with type 2 DM, have also been
associated with liver fat and NASH pathogenesis [45]. Con-
trarily to the observed in a previous study with type 2 DM
patients [6], in our study with premenopausal overweight
and obese women, both LSR and liver attenuation were
not associated with leptin, IL-6, TNF-α, and with any
other speciﬁc inﬂammatory and thrombotic risk factors
studied. Similar results were obtained when we analysed
the independent contribution of LSR to both metabolic
markers, after adjusted for age, total fat mass, and VAT
(data not shown). These results maybe be explained by
relatively “healthy” metabolic proﬁle found in our sample
when compared to the unfavourable proﬁle usually found in
type 2 DM patients.
The CT abdominal and thigh adipose and muscle tissue
assessments, as well as the broad list of metabolic features
measured and the considerable sample size (n = 140) are
some of the strengths of this study. Additionally, participants
were counseled to refrain from exercise at least 48 hours
prior to blood sampling, avoiding metabolic acute exercise
interferences.However,therearelimitationsinourstudythat
warrantmention.First,itisnoteworthythatliverattenuation
obtained by CT cannot quantify absolute liver fat because
attenuation of each voxel is a function of its lipid, lean tissue,
and water composition. Therefore, variations in each one
of the components may change the resultant attenuation,
adding diﬃculties in data interpretation. Second, despite
careful attention in ensuring bloods samples were taken
during the follicular stage of menses, we did not control
the diet prior blood sampling. Since lipid levels of liver and
muscle can present slightly acute diﬀerences depending on
diet, this issue may also slightly inﬂuence CT attenuations.Journal of Lipids 9
Third, the low prevalence of women (2.9%) presenting
a fatty liver found (as deﬁned by a LSR < 1) in our
study is also an important issue to consider since the
observations made in our study with overweight and obese
premenopausal women can not be extrapolated for obese
or diabetic patients presenting a dysmetabolic milieu totally
diﬀerentfromrelativelyhealthymetabolicsubjects.Finally,it
is well established that men and women (before menopause)
present diﬀerent body composition patterns. Adipose tissue
accumulation in overweight and obese men tends to be
concentrated in the abdominal area whereas women tend
to accumulate fat in gluteal-femoral area. It is also known
that these diﬀerent adipose tissue depots present diﬀerent
metabolic characteristics that might be responsible for the
body composition diﬀerences observed. In this sense, in our
study with overweight and obese premenopausal women,
the associations observed cannot be extrapolated for male
subjects, especially those related with the possible preventive
roleof thigh SFAT to liver lipotoxicity since severalmetabolic
characteristics present in female gluteal-femoral adipocytes
seem to be reduced in male adipocytes.
In summary, contrarily to previous observations made
in obese type 2 DM patients, thigh subfascial adiposity
was independent and inversely associated with liver fat in
overweight and obese women, suggesting that this thigh AT
compartment may play a preventive role against detrimental
liver ectopic fat storage. Conversely, our results emphasize
the contribution of a higher BMI and visceral AT, especially
if associated with hyperinsulinemia, dyslipidemia, and an
inﬂammatory and atherothrombotic proﬁle to the metabolic
cascade that dialectically interacts with liver lipotoxicity in
overweight and obese premenopausal Caucasian women.
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